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Abstract 
Background: Oral squamous cell carcinoma (OSCC) or cancers of oral cavity is one of the most common cancers 
worldwide with high rate of mortality and morbidity. At present, chemotherapy is one of the most effective treat‑
ments; however it often fails to meet the requirements in the clinical therapy. In the present study, we have success‑
fully formulated ligand‑decorated cancer‑targeted CDDP‑loaded PLGA‑PEG/NR7 nanoparticles and demonstrated 
the feasibility of using NR7 peptide for targeted delivery, rapid intracellular uptake, and enhanced cytotoxic effect in 
receptor‑overexpressed OSCC cancer cells.
Results: Nanosized particles were formed and sustained release patterns were observed for PLGA/NR7 nanoparti‑
cles. Significantly higher cellular uptake was observed in HN6 OSCC cancer cells and superior anticancer effects are 
observed from the optimized targeted nanoparticles. Furthermore, Live/Dead assay showed a higher extent of red 
fluorescence was observed for the cells exposed with PLGA/NR7 than compared with non‑targeted PLGA NP. The 
presence of the NR7‑targeting moiety on the surface of PLGA carriers could allow the specific receptor‑mediated 
internalization, enhanced cellular uptake, and higher cell killing potency. Especially, PLGA/NR7 NP exhibited a superior 
apoptosis effect in HN6 cancer cells with around ~45 % (early and late apoptotic stage) and ~59 % after 24 and 48 h 
incubation, respectively. It is apparent that the actively targeted micelles will deliver more anticancer agent to cancer 
cell than non‑targeted one.
Conclusion: Altogether, our results show the feasibility and promise of a cell‑targeted anticancer nanomedicine 
strategy that can be effective for the treatment of oral squamous cell carcinoma. The present work might be of 
great importance to the further exploration of the potential application of PLGA/NR7 in the clinically relevant animal 
models.
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Background
Oral squamous cell carcinoma (OSCC) or cancers of oral 
cavity is one of the most common cancers worldwide, 
especially in developing nations like China [1]. OSCC 
become a critical healthcare problem with high rate of 
mortality and morbidity [2]. Squamous cell carcinoma of 
the oral cavity accounts for close to  ~400,000 cases per 
year with a mortality rate of 50 % [3]. Present treatment 
options include surgery, radiotherapy, and conventional 
chemotherapy. Due to the specific location of anatomic 
structures (breathing and swallowing), surgical excision 
of tumor tissues in this region causes unnecessary dam-
age to adjacent or underlying anatomical structures [4]. 
Whereas, radiation therapy may have long-term side 
effects to the healthy cells which are associated with 
brain, spinal cord, and saliva glands (such as xerostomia 
and osteoradionecrosis). At present, chemotherapy is one 
of the most effective treatments; however it often fails 
to meet the requirements in the clinical therapy. Gener-
ally, conventional chemotherapeutics drugs exhibit poor 
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systemic stability, limited water solubility, unwanted 
drug-related side effects (bone marrow depression and 
nephrotoxicity), and relatively short half-life that prevent 
their further clinical application [5, 6]. Despite recent 
progress in the diagnosis of and therapeutic modalities 
for OSCC, overall survival rates have not improved and 
needs alternative therapeutic approaches.
In this regard, cis-Diaminedichloroplatinum (cisplatin, 
CDDP) is extensively used for the treatment of various 
cancers such as ovarian, testicular, colorectal, and oral 
squamous cancers [7, 8]. CDDP is recommended in mul-
tiple cancers owing to its strong synergistic anticancer 
effect either as single drug or in combination with other 
anticancer agents. CDDP kills cancer cell by inducing 
cross-linking of DNA by interfering with the cellular divi-
sions and activates the apoptosis pathways [9]. Addition-
ally, it suppresses the Bcl-2 protein in many cancer cells. 
Despite, its potential therapeutic effects, CDDP suffers 
from many serious side effects such as nephrotoxicity, 
neurotoxicity, gastrointestinal toxicity, hematological 
toxicity and ototoxicity [10, 11]. Therefore, effective con-
trolled delivery systems have to be designed to target to 
oral cancer sites and to avoid the shortcomings of con-
ventional chemotherapy treatments.
Recently, self-assembled polymeric nanoparticles, have 
received increased attention for their potential appli-
cation as a drug delivery carrier in cancer therapeu-
tics. The polymeric self-assembled nanoparticles offer 
some unique advantages including core–shell morphol-
ogy, high loading capacity, site-specific drug delivery, 
and avoids unwanted side effects of administered drug. 
For this purpose, biodegradable polymer, poly(lactic-
co-glycolic acid) (PLGA)-poly(ethylene) glycol (PEG) 
(PLGA-PEG) was selected due to its excellent systemic 
characteristics and biodegradability [12]. Several stud-
ies have reported that nanosized PLGA-PEG NP would 
effectively increase the intracellular concentration of 
anticancer drugs by enhancing the blood circulation time 
of nanocarriers and avoids the reticuloendothelial sys-
tem (RES) mediated clearance [13]. Moreover, polymeric 
nanoparticles with active targeting moiety will increase 
the target specificity. The epidermal growth factor (EGF) 
receptor is recognized as an important target for the 
development of treatment for cancer [14]. EGF receptor 
is highly expressed in human epithelial cancer cells such 
as OSCC. Several EGF-targeting therapeutic agents such 
as cetuximab and erlotinib have already been approved 
by the USFDA. In this line, NR7 peptide (NSVRGSR) 
which is based on alignment of the tripeptide motif with 
the EGF binding domain was selected [15]. Moreover, 
NR7 is the only peptide which not only appeared twice 
between these EGF receptor ligands but also contained 
tripeptide motifs relative to the mature EGF domain [16]. 
We expected that when NR7-conjugated delivery system 
is administered, it will enhance the overall chemothera-
peutic efficiency in cancers.
Herein, the main aim of present study was to develop 
a CDDP-loaded delivery system to target the oral squa-
mous cell carcinoma. For this purpose, PEG-PLGA poly-
mer was synthesized and conjugated with NR7 peptide. 
The CDDP-loaded PLGA NP was prepared by solvent-
evaporation method and evaluated in terms of size, 
shape, in vitro release study (physicochemical characteri-
zations). Further, target specificity was investigated in the 
in vitro conditions by means of cellular uptake of targeted 
and non-targeted NP in OSCC cancer cells. Cytotoxic 
effect of targeted and non-targeted NP was investigated 
by MTT assay, live-dead assay, and apoptosis analysis.
Results and discussion
Squamous cell carcinoma of the oral cavity accounts for 
close to  ~  400,000 cases per year with a mortality rate 
of 50  %. At present, chemotherapy is one of the most 
effective treatments; however it often fails to meet the 
requirements in the clinical therapy. Generally, conven-
tional chemotherapeutics drugs exhibit poor systemic 
stability, limited water solubility, unwanted drug-related 
side effects (bone marrow depression and nephrotoxic-
ity), and relatively short half-life that prevent their further 
clinical application. Cis-Diaminedichloroplatinum (cispl-
atin, CDDP) is one such drug which is extensively used 
for the treatment of various cancers such as ovarian, tes-
ticular, colorectal, and oral squamous cancers, however 
it suffers from many serious side effects. Studies have 
shown that nanocarriers caused better selective accumu-
lation of CDDP in tumors while lessening its distribu-
tion in normal tissue. Therefore, biodegradable polymer, 
poly(lactic-co-glycolic acid) (PLGA)-poly(ethylene) gly-
col (PEG) (PLGA-PEG) based self-assembled polymeric 
micelles was designed in the present study. The hydro-
philic poly(ethylene glycol) shell layer enables the parti-
cles to circulate for long time in the blood compartment 
which will facilitate its preferential accumulation in the 
tumor tissues. Furthermore, NR7 peptide (NSVRGSR) 
which is based on alignment of the tripeptide motif with 
the EGF binding domain was selected to actively target 
the anticancer drug to the specific cancer site (Fig. 1). We 
expected that when NR7-conjugated delivery system is 
administered, it will enhance the overall chemotherapeu-
tic efficiency in cancers.
In this study, PLGA-PEG was conjugated with NR7 
peptide to increase the tumor specificity. The so-formed 
block polymer exhibited a critical micellar concentration 
of 3.3 ×  10−8 mol/L. Our results are consistent or bet-
ter than the reported values. It has been earlier reported 
that micelles with a CMC of 8 × 10−7 mol/L was stable in 
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the blood circulation. In this regard, our micelles which 
showed much lower CMC value is expected to show a 
remarkable systemic performance.
Physicochemical characterization of nanoparticles
The CDDP-loaded PLGA NPs were formed by the self-
assembly of drug in the hydrophobic core of the poly-
meric micelles. After being dissolved in DMSO and 
dialyzed against water, CDDP was able to spontaneously 
self-assemble into micelles with hydrophobic PLGA core 
and hydrophilic PEG outer shell. The resulting NPs were 
expected to be nanometre range. The particle size and size 
distributions of NP were evaluate by dynamic light scat-
tering technique (DLS). The average size of drug-loaded 
PLGA NP was around  ~100  nm while a slight incre-
ment in size was observed for PLGA/NR7 NP (~135 nm) 
(Fig. 2a). The slight increase in size could be attributed to 
the presence of NR7 peptide on the surface of the nano-
particles. Nevertheless, both the NP system showed an 
excellent polydispersity index of PDI ~ 0.15. Despite the 
increase in the overall size, resulting size was in accord-
ance with literature for cancer drug delivery applications. 
It has been reported that micelles with an average size 
between 50- and 150-nm-diameter ranges, could eas-
ily avoid rapid renal clearance or leakage through nor-
mal vasculature, yet allow EPR-mediated accumulation 
through tumor-associated leaky vasculature [17, 18].
The morphology of optimized PLGA/NR7 NP was 
evaluated by means of transmission electron microscopy 
(TEM) (Fig. 2b). The PLGA/NR7 NP showed a nanosized 
particle with clear spherical morphology. The particles 
were uniformly distributed on the carbon-coated copper 
grid suggesting the success of the formulation technique. 
A darker core represents the hydrophobic PLGA core 
while a shallow outer layer (greyish) could be the PEG 
shell. Such a nanosized particle with spherical morphol-
ogy is expected to increase the systemic performance and 
anticancer effect.
Fig. 1 Schematic illustration of synthesis of PLGA‑PEG and PLGA‑PEG‑NR7. The self‑assembly of cisplatin (CDDP) with PLGA‑PEG‑NR7 block copoly‑
mer into a polymeric micelles is presented
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In vitro drug release study
The drug release profile of PLGA NP and PLGA/NR7 
NP was investigated by dialysis method under simulated 
physiological condition (PBS, pH 7.4) at 37 °C. The results 
revealed a constant and controlled release of CDDP from 
the nanoparticulate systems (Fig.  3). Throughout the 
study period (96 h), CDDP was released in a controlled 
manner with no burst release pattern or bi-phasic release 
pattern. Lack of burst release pattern indicates that the 
drug was stably loaded in the hydrophobic core of the 
polymeric micelles. Importantly, presence of NR7 pep-
tide on the surface of NP did not affect the release of 
anticancer drug. A slight decrease in the release rate of 
CDDP from PLGA/NR7 NP might be attributed to the 
aforementioned reason. Overall, ~85 % of drug released 
from PLGA NP and ~80 % of drug released from PLGA/
NR7 NP. The release study clearly showed that PLGA NP 
could effectively protect the drug in the systemic circula-
tion which will allow the preferential accumulation of NP 
in the tumor tissues. It could be expected that release will 
be faster in the tumor acidic pH owing to the intracellular 
compartments (endosomes and lysosomes).
In vitro cellular uptake study
Quantitative and fluorescent studies were performed to 
investigate the binding affinity of targeted and non-tar-
geted polymeric micelles. For this purpose, PLGA NP 
was loaded with Rho B fluorescent dye instead of CDDP. 
As seen from Fig.  4a, cells incubated with PLGA and 
PLGA/NR7 NP showed appreciable intracellular uptake. 
Notably, NR7 conjugated polymeric nanoparticle showed 
significantly (p < 0.01) higher cellular uptake than that of 
non-targeted PLGA NP. The influence of targeting ligand 
on the NP surface was visible immediately after 1  h of 
incubation, wherein PLGA/NR7 NP exhibited more than 
20  % of cellular internalization compared to  <10  % for 
non-targeted NP. The trend continued up to 24  h. Two 
different phase of cellular uptake was observed. First, 
steady or faster rate of cell uptake was seen in first 12 h 
of study, followed by a relatively slower cellular uptake (of 
less than 10  %). Overall, PLGA/NR7 NP showed  ~70  % 
of NP uptake comparing to meagre ~34 % for PLGA NP. 
From the result, it is apparent that the actively targeted 
micelles will deliver more anticancer agent to cancer 
cell than non-targeted one. These data suggest a role for 
receptor-mediated internalization of the actively targeted 
PLGA/NR7 NP.
The fluorescence microscopy images further sup-
ported the quantitative estimated for NP uptake. For 
this purpose, lysosome was stained with Lysotracker 
Green and the nuclear region was stained with DAPI. As 
seen from Fig. 4b, PLGA/NR7 NP treated cells showed 
remarkably high fluorescence intensity (70 %) than com-
pared to PLGA NP treated cells (28  %). The difference 
between cellular internalization of two groups could be 
the mechanism of cellular uptake. A typical endocyto-
sis-mediated active uptake could be the main reason 
Fig. 2 a Particle size distribution of CDDP‑loaded PLGA‑PEG‑NR7 nanoparticles. b TEM image of PD/IFS
Fig. 3 The release profile of CDDP from PLGA NP and PLGA/NR7. The 
release study was performed in phosphate buffered saline at 37 °C. 
The study was carried out for 96 h
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behind the high uptake of NR7 peptide conjugated NP 
group, whereas normal membrane based passive pro-
cesses might be involved in non-targeted NP [19]. This 
resulted in low colocalization of red fluorescence with 
lysosomal (green) fluorescence. These data suggest that 
without active NR7 targeting, the intracellular uptake 
of NP would be significantly less. Similar mechanisms 
have been recently reported for a number of ligand 
decorated drug-loaded block co-polymer micelle for-
mulations targeted to relevant cancer biomarkers like 
EGFR, folate receptor, and integrin αVβ3. The nano-
formulation is expected to destabilize and disassemble 
in the lysosomal compartment to allow CDDP release 
which will then travel to nucleus and perinuceus region 
and enhance the anticancer efficacy [20]. These results 
provide the rationale that upon in  vivo administra-
tion; these nanoformulations may allow targeted CDDP 
delivery, tumor-selective accumulation, and rapid intra-
cellular uptake.
In vitro cytotoxicity assay
The anticancer efficacy of free CDDP, PLGA NP, and 
PLGA/NR7 NP was evaluated on squamous cell carci-
noma (HN6) using MTT assay. The cells were treated 
with individual formulations at various concentrations 
and incubated for 24 and 48 h, respectively. First, blank 
nanoparticle was incubated in HN6 cells and noted its 
cytotoxic effect. As seen from Fig. 5a, blank polymer did 
not induce any appreciable toxicity and the cell viability 
remained more than 95  % throughout all the concen-
trations tested. The high cell viability of blank poly-
mer indicates its excellent biocompatibility and would 
be suitable for the systemic administration or cancer 
targeting.
The free drug as well as drug-loaded formulations 
exhibited a dose-dependent and time-dependent cyto-
toxicity on HN6 cancer cells (Fig.  5b, c). Specifically, 
PLGA/NR7 NP showed a significantly (p  <  0.01) higher 
cytotoxic effect than compared to either free CDDP 
Fig. 4 a Intracellular uptake of PLGA NP and PLGA/NR7 NP in HN6 squamous cell carcinoma. Rhodamine B was used as a fluorescent dye. The 
uptake is shown as a percentage of total amounts of NP (dye) incubated with the cancer cells. b Representative confocal microscopy images of 
targeted and non‑targeted NP in HN6 cancer cells. The cells are stained with Lysotracker lysosomal stain and DAPI was used to stain the nucleus. 
**p < 0.01 and *p < 005 is the statistical difference between the cellular uptake of two formulations
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or PLGA NP. The results were consistent with cellular 
uptake study wherein NR7 active targeting moiety con-
jugated group showed an enhanced cellular uptake. The 
presence of the NR7-targeting moiety on the surface of 
PLGA carriers could allow the specific receptor-medi-
ated internalization, enhanced cellular uptake, and higher 
cell killing potency. Increased anticancer activity with 
the increase in the incubation of formulations could be 
attributed to higher intracellular concentration of anti-
cancer drugs [21]. The doses for cytotoxic effect were 
determined based on IC50 values of these NPs. The IC50 
value of free CDDP, PLGA NP, and PLGA/NR7 NP were 
observed to be 4.94, 2.61, and 0.75  µg/ml, respectively 
after 24  h of incubation. This is in accordance with the 
fact that at shorter time periods, for the NR7-targeted 
PLGA nanoformulation, a higher amount of intracel-
lular uptake of CDDP occurs via receptor-mediated 
mechanism, compared to the time-dependent passive 
uptake of the nontargeted formulation. This results in the 
superior anticancer effect of the NR7 conjugated formu-
lations [22].
Live/dead assay
The cytotoxicity assay was further confirmed by Live/
Dead assay. The cells were treated with respective for-
mulations and then incubated with Calcein AM and 
Ethidium bromide dye as representative live and dead 
cell markers. As seen from Fig.  6, higher extent of red 
fluorescence (68  %) was observed for the cells exposed 
with PLGA/NR7 than compared with non-targeted 
PLGA NP (39  %). Consistent with cytotoxicity assay, 
free CDDP showed 40  % more viable cells (green fluo-
rescence) and the red fluorescence was significantly 
decreased. Whereas extent of red and green fluorescence 
Fig. 5 a Cytotoxicity assay of blank nanoparticles in HN6 cancer cells. b Cytotoxicity analysis of free CDDP, PLGA NP, and PLGA/NR7 NP in HN6 
cancer cells. Different amounts of formulations were added from 0.001 to 100 µg/ml to each well and incubated for 24 and 48 h. Survival rate of 
HN6 cell was determined by MTT assay. Data were obtained from three independent triplicate experiments and were presented as mean ± S.D. 
**p < 0.01 is the statistical difference between the cytotoxicity of PLGA/NR7 and CDDP
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is an indication of dead cells and live cells, respectively. 
Despite the cytotoxic effect of PLGA/NR7 carrier, slight 
presence of green cells suggest that drug release from 
the nanoparticle in a sustained manner and therefore 
kills in a time-dependent manner. Generally, Calcein AM 
can easily enter cells by diffusion and it is converted to 
Calcein by the intracellular esterase which stains the live 
cells green. The damaged or dead cells are stained red 
with Ethidium bromide.
Cell apoptosis assay
Annexin V-FITC/PI staining assay was used to inves-
tigate the mode of cell death and apoptosis for free 
CDDP, PLGA NP, and PLGA/NR7 NP treated groups. 
Annexin V/FITC detects the phosphatidylserine exter-
nalization which characterizes early apoptotic events. 
Cancer cell death can be programmed (apoptosis) or 
non-programmed (necrosis). The apoptosis-inducing 
effect of formulations was evaluated by counting the 
early apoptosis and late apoptosis. The results clearly 
showed a remarkable apoptosis effect of all the formu-
lations (Fig.  7). Especially, PLGA/NR7 NP exhibited 
a superior apoptosis effect in HN6 cancer cells with 
around ~45 % (early and late apoptotic stage) and ~59 % 
after 24 and 48  h incubation, respectively. One could 
easily see that at 24 h, early apoptosis was predominant 
however with the increase in the incubation time; cells 
migrate to late apoptosis stage, which is consistent with 
many published reports. On the other hand, PLGA NP 
showed around  ~26 and  ~43  % apoptosis after respec-
tive time interval. The result was consistent with the cel-
lular uptake analysis and MTT-based cytotoxicity assay. 
The plausible reason for such superior anticancer activ-
ity by PLGA/NR7 nanoparticles could be attributed to 
the in  vitro release profile and cell uptake studies. The 
results indicate that the high cytotoxicity induced by 
PLGA/NR7 NP can mainly be attributed to apoptosis 
induction which was in turn due to the high cellular 
internalization of targeted nanoparticles.
Conclusion
In conclusion, we have successfully formulated ligand-
decorated cancer-targeted CDDP-loaded PLGA-PEG/
NR7 nanoparticles and demonstrated the feasibility of 
using NR7 peptide for targeted delivery, rapid intracel-
lular uptake, and enhanced cytotoxic effect in recep-
tor-overexpressed OSCC cancer cells. Nanosized 
particles were formed and sustained release patterns 
were observed for PLGA/NR7 nanoparticles. Signifi-
cantly higher cellular uptake was observed in HN6 OSCC 
cancer cells and superior anticancer effects are observed 
from the optimized targeted nanoparticles. Furthermore, 
Live/Dead assay showed a higher extent of red fluores-
cence was observed for the cells exposed with PLGA/
NR7 than compared with non-targeted PLGA NP. The 
presence of the NR7-targeting moiety on the surface of 
PLGA carriers could allow the specific receptor-medi-
ated internalization, enhanced cellular uptake, and higher 
cell killing potency. Especially, PLGA/NR7 NP exhib-
ited a superior apoptosis effect in HN6 cancer cells with 
around ~45 % (early and late apoptotic stage) and ~59 % 
after 24 and 48  h incubation, respectively. It is appar-
ent that the actively targeted micelles will deliver more 
anticancer agent to cancer cell than non-targeted one. 
Altogether, our results show the feasibility and promise 
of a cell-targeted anticancer nanomedicine strategy that 




PLGA ([η]  =  0.32–0.44 dL/g; 50:50) and CDDP was 
purchased from Sigma-Aldrich (China). Cisplatin, PEG-
diamine (Mn ~ 2000) was purchased from Laysan Bio Inc 
Fig. 6 The cytotoxicity potential of free CDDP, PLGA NP, and PLGA/NR7 NP were evaluated by Live/Dead assay. Cells were stained with a live/dead 
cell viability assay (Invitrogen). This assay uses two fluorescent probes, calcein AM and ethidium homodimer‑1
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(Arab, AL). 1-ethyl-3 (3-dimethylaminopropyl) carbod-
imide (EDC) was purchased from Sigma Aldrich, China. 
All other chemicals were of reagent grade and used with-
out further purifications.
Fabrication of PLGA‑PEG block copolymer
PLGA-PEG was fabricated using carbodiimide coupling 
reaction. Briefly, 10 g of PLGA was activated by dissolv-
ing in DMSO and followed by the addition of EDC and 
NHS and the mixture was allowed to react for 15 h under 
constant nitrogen atmosphere. PLGA-NHS was collected 
by the addition of cold ether and filtered. The PLGA-PEG 
was formed by dissolving both PLGA-NHS and PEG 
diamine at a ratio of 30:1 in DMSO and allowed to react 
for 24  h under constant nitrogen atmosphere at room 
temperature. The final product PLGA-PEG-NH2 was 
precipitated by excessive acetonitrile and washed with ice 
cold methanol. The unreacted PEG-diamine was sepa-
rated by dialysis method and dried under vacuum.
PLGA-PEG-NR7 was prepared by chemical conjuga-
tion of carboxylic group of peptide with the amino group 
of PLGA-PEG copolymer in the presence of carbodiim-
ide hydrochloride (EDC) and N-hydroxysuccinimide 
(NHS). The PLGA-PEG and NR7 peptide was mixed at a 
ratio of 10:1 and allowed to react at room temperature for 
3 h. The final product was precipitated, centrifuged, and 
freeze dried.
Preparation of CDDP‑loaded polymeric nanoparticles
CDDP and PLGA-PEG was dissolved in acetone/dichlo-
romethane (1/1 v/v) mixture at a ratio of 5:1. This organic 
solution was slowly added to 10  mL of 0.25  % polyvi-
nyl alcohol and the solution was immediately sonicated 
(3 min) and mechanically stirred at room temperature for 
2  h. The drug-loaded nanoparticles (NP) was collected 
by centrifuging at high speed and re-suspended in ultra-
pure water. The CDDP-loaded PLGA-PEG NP (PLGA/
NR7) was stored at 4 °C until further analysis.
Live/dead assay
Live/dead assay was performed using a Live/dead cell 
viability assay Kit (Invitrogen). Calcein AM and eth-
idium homodimer-1 was identified as markers for live 
and dead cell, respectively. Nonfluorescent calcein-AM 
is hydrolysed by live cell into green fluorescent calcein, 
whereas ethidium homodimer-1 can only pass through 
dead cells membrane. For this purpose, cells were seeded 
in a 12-well plate and incubated for 24 h. The cells were 
treated with respective formulations and further incu-
bated for 24 h. Subsequently, the cells were rinsed twice 
with PBS before the fluorochromes were added and incu-
bated for 45  min. Fluorescence images were then taken 
using a Floid Cell Imaging Station (Molecular Probes Life 
Technology, France).
Particle size and size distribution analysis
The average particle size and size distribution analysis 
was performed using a Zetasizer Nano-S90 (Malvern 
Instruments, Malvern, UK) and a 633  nm He–Ne laser 
beam at a fixed scattering angle of 90°. A dilute solution 
of NP was used to analyse the particle size. The experi-
ments were performed in triplicates.
Fig. 7 Annexin V‑FITC FACS apoptosis analysis of HN6 cancer cells after treatment with free CDDP, PLGA NP, and PLGA/NR7 NP for 24 and 48h, 
respectively. a indicates PI positive cells (necrosis), b represents late apoptosis (PI and Annexin positive cells), c represents healthy cells (PI and 
Annexin negative cells), d early apoptosis (Annexin positive cells)
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Transmission electron microscopy
The morphology and size of particles were observed by 
using the HITACHI 7650 transmission electron micro-
scope (TEM) from Hitachi, Ltd (Kyoto, Japan).  Before 
the examinations, NP dispersion was diluted many times 
with ultra-pure water. The aqueous solution was dropped 
on the carbon coated copper grid and counter stained 
with 2 % phosphotungistic acid. The samples were dried 
using an infrared lamp and viewed under TEM.
Drug loading
The drug encapsulation efficiency (EE %) was expressed 
as the percentage of the amount of CDDP encapsulated 
in the nanoparticles to the total amount of CDDP ini-
tially used. The drug loading (DL  %) was expressed as 
the percentage of the amount of CDDP encapsulated in 
the nanoparticles to the total amount of nanoparticles 
initially used. The loading efficiency and loading capac-
ity was determined as follows. In brief, 10 mg of lyophi-
lized NP was dissolved in 5 ml of DMSO and sonicated 
for 15 min. The organic solution was centrifuged and the 
supernatant was used to calculate the amount of drug 
loaded. The supernatants were then determined using 
the ICP-MS with the following experimental parameters: 
plasma flow (15 L/min), auxiliary flow (1.5 L/min), radio 
frequency power (1300  W), sampling depth (8.4  mm), 
atomizing chamber temperature (2  °C), and nebulizer 
flow (1.0 L/min).
Drug release study
The CDDP release from the NP system was determined 
using a dialysis method. Briefly, 30 mg of PLGA NP lyo-
philized powder was dissolved in 1 ml of water and sealed 
in a dialysis tube. The dialysis tube was in turn placed in 
a 50 ml of Falcon tube containing 25 ml of release media. 
Selective release media including phosphate buffered 
saline (PBS, pH 7.4) was used. The sampling was done 
at specific time points such as 1,2,4.6,8,10,12,24,48,72,9
6,120 h. At each sampling point, 1 ml of release sample 
was withdrawn and replaced with equal volume of fresh 
media. The released IFS content in the released medium 
was determined as reported previously. The CDDP 
encapsulated in nanoparticles was measured according 
to the previous method by using the HITACHI P-4010 
inductively coupled plasma mass spectrometry (ICP-MS) 
from Hitachi Ltd (Kyoto, Japan).
Cytotoxicity assay
The human OSCC cell lines HN-6 was cultured in 
DMEM supplied with 10 % FBS and antibiotics (50 units/
mL penicillin and 50 units/mL streptomycin) at 37  °C 
in a humidified atmosphere containing 5  % CO2. The 
cytotoxicity potential of individual formulations were 
evaluated by means of MTT colorimetric assay. Cells 
(1 × 104 per well) were seeded in a flat-bottomed 96 well 
plate and incubated at 37 °C and in 5 % CO2. Cells were 
exposed to blank NPS and drug-loaded formulations at 
various dose concentrations. The cells were incubated 
for 24 and 48 h, respectively. Cells were then treated with 
MTT reagent (20 μL/well volume from 5  mg/mL solu-
tion in PBS) for 3 h at 37 °C. DMSO (100 μL) was added 
to each well to dissolve the formazan crystals. The opti-
cal density (OD) was recorded at 570 nm in a microplate 
reader, and percentage of residual cell viability was deter-
mined. The cell cytotoxicity of different formulations is 
defined as the relative viability, which is the ratio of the 
number of live cells to that of the control cells (100 %).
Fluorescence microscopy
The cellular uptake efficiency of PLGA NP and PLGA/
NR7 NP in OSCC was evaluated by fluorescence and 
confocal laser scanning microscopy. HN-6 cells were 
seeded into 24-well plates (5 × 104 cells/well) and incu-
bated for 24  h. The medium was then replaced with 
fresh DMEM culture medium containing PLGA NP and 
PLGA/NR7 NP. For the cellular uptake studies, CDDP 
was replaced with Rho B as a fluorescent marker. The 
cells were incubated for various time points up to 24 h. 
At each time points, cells were washed; extracted and 
cellular uptake was calculated in terms of extent of fluo-
rescent intensity.
The cellular internalization process was further con-
firmed by confocal laser scanning microscopy. HN-6 cells 
were seeded into 6-well plates (1  ×  106 cells/well) and 
incubated for 24 h. Cells were treated with PLGA NP and 
PLGA/NR7 NP, respectively. The cells were then washed 
with PBS and fixed with 4  % paraformaldehyde for 
15 min at room temperature, and the slides were rinsed 
with cold PBS three times. The cells were observed using 
fluorescence microscope (Olympus Bx60).
Apoptosis assay
Cells (1 × 105 per well) were seeded in a flat-bottomed 
12 well plate and incubated at 37 °C and in 5 % CO2. Cells 
were exposed to different drug-loaded formulations at 
various dose concentrations. The cells were incubated for 
24 h and were harvested and washed with PBS after the 
treatment. The cells were first incubated with 100 μL of 
binding buffer and stained with 5 μL of Annexin V-FITC 
and 5 μL of propidium iodide (PI) from kit according 
to manufacturer’s instruction (BD Bioscience, China) at 
room temperature for 15 min in the dark. The cells were 
then analyzed by flow cytometry (BD LSR II Analyzer), 
and 10,000 cells were counted.
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Statistical analysis
Statistical analyses were carried out using SigmaStat ver-
sion 2.0 (SPSS, Inc, Chicago, IL, USA). Unless stated oth-
erwise, all experiments were performed in triplicate, and 
results are presented as mean values ±  standard devia-
tion. ANOVA testing was employed to determine the sta-
tistical significance with p < 0.05.
Abbreviations
CDDP: Cisplatin; OSCC: oral squamous cell carcinoma; PLGA: poly (lactic‑b‑
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receptor.
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